Port Erin Biopharma Investments Ltd Net Asset Value(s) (9575E)
October 24 2018 - 2:00AM
UK Regulatory
TIDMPEBI
RNS Number : 9575E
Port Erin Biopharma Investments Ltd
24 October 2018
24 October 2018
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 September 2018
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at
closing on 30 September 2018 was 7.80 pence per share, including
un-invested cash of GBP307,807. The portfolio is valued under IFRS
at bid price.
Net Assets stand at GBP1.8 million including investments of
GBP1.2 million. This quarter's NAV represents a decrease of 7.14%
from the previous valuation of 8.40 pence per share, which included
un-invested cash of GBP555,293. No management fee is due to
Shellbay Investments Limited.
SalvaRX Group Plc gained 126% during the last quarter,
reflecting announcements regarding proposed disposal and demerger
with Portage Biotech Inc. Upon the announcement, shares jumped 76%
reaching a peak of 78.5 per share.
During the quarter, the Company invested US$250,000 into
BlueNalu Inc. A pioneer in the field of cellular aquaculture(TM),
announced the closing of a $4.5 million seed round, just two months
after announcing the launch of the company. BlueNalu's cellular
aquaculture(TM) process will provide an alternative to current
industry practices in which fish are farmed or wild-caught.
BlueNalu will ultimately produce real seafood products directly
from fish cells, in a way that is healthy for people, humane for
animals, and sustainable for our planet.
Of our unquoted companies, Spiritus Pharmaceuticals Inc has been
written down to zero value."
Unaudited to
30 September 2018 GBP
Fixed Assets
Investments 1,269,719
Current Assets
Loan receivable 232,925
Sundry Debtors 26,995
Uninvested cash 307,807
Current Liabilities
Creditors: amounts due (28,403)
----------------------
1,809,043
Capital and Reserves
Share Capital 23
Share Premium 1,890,142
Reserves (81,122)
----------------------
1,809,043
Shares in Issue 23,195,558
Net Asset Value per share 7.80 pence
Portfolio Details
Investments as at 30 June 2018 Value % of Total Portfolio
Regent Pacific Group Limited GBP345,727 27.23%
SalvaRX Group plc GBP123,148 9.70%
Summit Therapeutics plc GBP19,509 1.54%
Other quoted holdings GBP27,326 2.15%
Other unquoted holdings GBP754,009 59.38%
Total GBP1,269,719 100.00%
For further information, please contact:
Port Erin Biopharma Beaumont Cornish Limited Optiva Securities
Investments Limited Limited
The Company Nomad Broker
Denham Eke Roland Cornish/James Biddle Jeremy King/Ed McDermott
+44 (0) 1624 639396 +44 (0) 207 628 3396 +44 (0) 203 137 1904
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NAVKMMZGVFKGRZM
(END) Dow Jones Newswires
October 24, 2018 02:00 ET (06:00 GMT)
Agronomics (LSE:ANIC)
Historical Stock Chart
From Apr 2024 to May 2024
Agronomics (LSE:ANIC)
Historical Stock Chart
From May 2023 to May 2024